Physician profile
Jeffrey Mathis
NPI 1215918958
$6,894.01
in general payments reported to CMS, 2019-2025
39 companies · $1,307 in 2025
The $1,307 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $913 · 2020: $558 · 2021: $720 · 2022: $1,027 · 2023: $1,140 · 2024: $1,229 · 2025: $1,307.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,676.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,676.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $937.34 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $668.37 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $653.60 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $566.52 | 2019-2025 | Xifaxan, Trulance, Cycloset |
| Abbvie INC. | $462.90 | 2020-2025 | |
| Amgen INC. | $415.64 | 2019-2025 | Otezla, Repatha, Krystexxa |
| Lilly USA, LLC | $394.75 | 2019-2025 | Mounjaro, Zepbound |
| Abbott Laboratories | $390.47 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Amarin Pharma, INC. | $332.19 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $285.80 | 2019-2024 | Xarelto |
| Glaxosmithkline, LLC. | $260.32 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astellas Pharma US INC | $219.03 | 2019-2024 | Veozah, Myrbetriq |
| Exact Sciences Corporation | $132.27 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $121.72 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $112.25 | 2020-2022 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Mathis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.